|
|
Volumn 28, Issue 1 Suppl 3, 2001, Pages 20-27
|
|
Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
MONOCLONAL ANTIBODY;
PACLITAXEL;
TRASTUZUMAB;
BREAST TUMOR;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
DRUG EFFECT;
GENETICS;
HEART;
HUMAN;
METABOLISM;
PROTO ONCOGENE;
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS;
DOXORUBICIN;
GENES, ERBB-2;
HEART;
HEART FAILURE, CONGESTIVE;
HUMANS;
PACLITAXEL;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
RECEPTOR, ERBB-2;
MLCS;
MLOWN;
|
|
EID: 0035259989
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: 10.1053/sonc.2001.22813 Document Type: Review |
|
Times cited : (82)
|
|
References (35)
|
